CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) .
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | European Medicines Agency (EMA) | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals